Christopher Pericak and Caitlin Visek
Despite buzz at the recent ASTRO meeting about new radiation therapy technology, the ViewRay platform, we've seen a sharp falloff in chatter about this innovative technology. Our research team has spoken to several early adopters, but questions from interested buyers have been few and far between. This is somewhat unexpected, since the technology gets us closer than ever to the “holy grail” of radiation therapy: real-time adaptive treatment.
Can’t risk purchasing the ViewRay platform? Try MRI simulation.
Christopher Pericak and David Gaffin
On day three of American Society for Radiation Oncology (ASTRO), we’ve gotten some relief from the inclement weather and are excited to resume our coverage of the 2012 conference.
Our discussions today continued to unravel some of the major themes of the conference, while also providing the opportunity to take a closer look on the elephant-sized (or larger!) particle accelerator in the room: proton beam therapy.
We’ve heard much about the importance of cost reduction in radiation oncology in general, including plenty of facts and figures, putting this field at the forefront of cost growth within the health care industry. While the community certainly seems dedicated to reducing these costs, radiation oncology is still a capital intensive specialty that requires substantial investment to solve a range of complex problems.
ASTRO 2012: What does it take to reduce the cost of proton therapy?
David Gaffin and Christopher Pericak
The Oct. 29 proceedings of the 2012 annual meeting of the American Society for Radiation Oncology were disrupted by Hurricane Sandy, the storm which has impacted much of the East Coast.
Our thoughts are with those most negatively affected by the storm. However, we are able to provide coverage on yesterday's scientific sessions, vendor presentations, and a keynote address that is sure to significantly influence how the radiation oncology industry sets its research agenda and clinical goals across the next year.
ASTRO 2012: Industry turns to value-based care and technology